In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Myomo, Inc.

https://myomo.com/

Latest From Myomo, Inc.

Gazyva, Imfinzi Launched Following Japan Listing, Entyvio In The Wings

Japan has granted reimbursement prices to two anticancer antibodies and other products as it supports the availability of new, higher priced therapies in areas of high medical need, including through early access, while Takeda’s Entyvio is also set for launch.

Japan Commercial

Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication

Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.

Japan Approvals

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
UsernamePublicRestriction

Register